Metropolis Healthcare valuation

Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
Price multiples — at each FY-end close
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
56.95×————
7.59×————
6.72×————
38.34×————
Enterprise multiples
6.62×————
26.80×————
39.43×————
Yield
1.8%————
2.6%————
Reference — adjusted share basis
₹553.85————
₹9.72₹9.17₹6.99₹6.16₹6.89
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

METROPOLIS₹553.85

Metropolis Healthcare Ltd.

· Pharma & Health
₹ CrorePeersLALPATHLABVIJAYATHYROCAREMARKSANSPARKHOSPSJLHLRUBICONHCGMcap ₹11,483 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
Multiples — ₹ Crore base
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Price Multiples — at each FY-end close
P/E————56.95
P/B————7.59
P/Sales————6.72
Price to Free Cash Flow————38.34
Enterprise Multiples
EV/Sales————6.62
EV/EBITDA————26.80
EV/EBIT————39.43
Yield
Earnings Yield %————1.76
FCF Yield %————2.61
Reference — adjusted share basis
Price (FY-end close, adj.)————553.85
EPS (adj.)6.896.166.999.179.72
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.